Table 2 Comparison of NOACs utilization in AF patients before and after recruited at AFSC (n = 299)
Variables | Before AFSC | After AFSC | P-value# |
|---|---|---|---|
NOAC | 175 (58.5) | 247 (82.6) | < 0.001 |
CHA2DS2-VASc score 2–4 | 11 (3.7) | 18 (6.0) | |
CHA2DS2-VASc score ≥ 5 | 164 (54.8) | 229 (76.6) | |
Dabigatran | 90 (30.1) | 105 (35.1) | |
Apixaban | 52 (17.4) | 139 (46.5) | |
Rivaroxaban | 25 (8.4) | 3 (1.0) | |
Warfarin | 8 (2.7) | 0 | |
non-NOAC | 124 (41.5) | 52 (17.4) | < 0.001 |
CHA2DS2-VASc score 2–4 | 18 (6.0) | 11 (3.7) | |
CHA2DS2-VASc score ≥ 5 | 106 (35.5) | 41 (13.7) | |
Aspirin | 115 (38.5) | 36 (12.0) | |
Clopidogrel | 3 (1.0) | 3 (1.0) | |
None | 6 (2.0) | 13 (4.3) |